Novartis (NVS) News Today

Novartis AG (NYSE: NVS) shares remain under pressure after two late-stage drug-trial failures raised concerns about the company’s growth pipeline and the effectiveness of its acquisition strategy. The setbacks have also prompted calls from a major shareholder for board changes, increasing governance uncertainty.

• Positive Sentiment: The stock showed signs of rebounding after its steep selloff, suggesting some investors may view the decline as an overreaction and remain confident in Novartis’s established medicines portfolio. Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
• Neutral Sentiment: Investors are focusing on how Novartis deployed roughly $30 billion in recent deals, as several acquired programs have encountered clinical setbacks. The scrutiny could lead to changes in capital-allocation priorities, deal approval processes or board composition. Focus: Novartis investors turn spotlight on M&A after trial setbacks
• Negative Sentiment: Experimental drug del-desiran failed to produce a statistically significant improvement in a late-stage trial for myotonic dystrophy type 1. The failure removes a potentially important growth asset and adds to concerns about Novartis’s pipeline. Drug Trial Setbacks Raise Questions Over Novartis’s Growth Pipeline
• Negative Sentiment: Del-desiran was the second major trial setback in a short period, contributing to a sharp weekly selloff and making investors question whether acquisitions are generating sufficient pipeline value. Deutsche Bank responded by cutting its view on the stock. Novartis extends selloff as Deutsche Bank cuts on twin drug trial setbacks
• Negative Sentiment: A major shareholder has called for a board shake-up, arguing that stronger oversight is needed after the trial failures and share-price decline. The challenge adds reputational and execution risk for management. Major Novartis shareholder calls for board shake-up after drug trial setbacks